Name: Eli Lilly and Company (NYSE:LLY) Shares Purchased by Oxbow Advisors LLC
Brand: rivertonroll.com
SKU: rivertonroll-com-1
Availability: OnlineOnly

critic

Eli Lilly and Company (NYSE:LLY) Shares Purchased by Oxbow Advisors LLC

preview

Skip to main contentPosted by onOxbow Advisors LLC grew its holdings in Eli Lilly and Company (NYSE:LLY – Free Report) by 6.6% in the second quarter, according to its most recent disclosure with the Securities &amp; Exchange Commission. The fund owned 845 shares of the company’s stock after buying an additional 52 shares during the period. Oxbow Advisors LLC’s holdings in Eli Lilly and Company were worth $396,000 as of its most recent filing with the Securities &amp; Exchange Commission.Several other hedge funds and other institutional investors have also recently modified their holdings of LLY. Guyasuta Investment Advisors Inc. raised its holdings in shares of Eli Lilly and Company by 4.6% during the 2nd quarter. Guyasuta Investment Advisors Inc. now owns 3,024 shares of the company’s stock worth $1,418,000 after acquiring an additional 132 shares during the period. Banco Bilbao Vizcaya Argentaria S.A. boosted its holdings in Eli Lilly and Company by 4.8% in the 1st quarter. Banco Bilbao Vizcaya Argentaria S.A. now owns 82,966 shares of the company’s stock valued at $28,449,000 after purchasing an additional 3,768 shares during the last quarter. Baystate Wealth Management LLC grew its stake in shares of Eli Lilly and Company by 688.2% in the 2nd quarter. Baystate Wealth Management LLC now owns 3,736 shares of the company’s stock valued at $1,752,000 after buying an additional 3,262 shares during the period. Simon Quick Advisors LLC increased its holdings in shares of Eli Lilly and Company by 13.0% during the 2nd quarter. Simon Quick Advisors LLC now owns 1,874 shares of the company’s stock worth $879,000 after buying an additional 215 shares during the last quarter. Finally, Martin Capital Partners LLC purchased a new stake in shares of Eli Lilly and Company during the 2nd quarter valued at approximately $234,000. 81.38% of the stock is owned by hedge funds and other institutional investors.Several research analysts recently weighed in on the company. Cantor Fitzgerald reiterated an “overweight” rating and issued a $630.00 price objective on shares of Eli Lilly and Company in a research report on Monday, October 23rd. Truist Financial raised their price objective on Eli Lilly and Company from $525.00 to $600.00 and gave the stock a “buy” rating in a research report on Wednesday, August 9th. Credit Suisse Group upped their target price on shares of Eli Lilly and Company from $490.00 to $580.00 and gave the company an “outperform” rating in a research report on Wednesday, August 9th. Morgan Stanley lifted their price target on shares of Eli Lilly and Company from $640.00 to $673.00 and gave the company an “overweight” rating in a research report on Wednesday, October 11th. Finally, BMO Capital Markets upped their price objective on shares of Eli Lilly and Company from $565.00 to $633.00 and gave the stock an “outperform” rating in a report on Wednesday, August 9th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and nineteen have given a buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $555.83.Get Our Latest Stock Report on Eli Lilly and CompanyIn related news, major shareholder Lilly Endowment Inc sold 3,000 shares of the business’s stock in a transaction that occurred on Thursday, August 10th. The stock was sold at an average price of $528.13, for a total transaction of $1,584,390.00. Following the completion of the sale, the insider now owns 100,696,849 shares in the company, valued at $53,181,026,862.37. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. In other Eli Lilly and Company news, EVP Alonzo Weems sold 1,148 shares of the firm’s stock in a transaction dated Tuesday, September 12th. The stock was sold at an average price of $590.98, for a total transaction of $678,445.04. Following the transaction, the executive vice president now owns 7,760 shares of the company’s stock, valued at $4,586,004.80. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, major shareholder Lilly Endowment Inc sold 3,000 shares of the business’s stock in a transaction dated Thursday, August 10th. The shares were sold at an average price of $528.13, for a total value of $1,584,390.00. Following the completion of the sale, the insider now directly owns 100,696,849 shares of the company’s stock, valued at $53,181,026,862.37. The disclosure for this sale can be found here. In the last ninety days, insiders sold 907,655 shares of company stock valued at $21,078,714,805. 0.13% of the stock is currently owned by corporate insiders.Shares of Eli Lilly and Company stock opened at $565.71 on Tuesday. The company has a quick ratio of 0.87, a current ratio of 1.13 and a debt-to-equity ratio of 1.63. Eli Lilly and Company has a 52-week low of $309.20 and a 52-week high of $629.97. The company has a market capitalization of $537.02 billion, a P/E ratio of 78.68, a P/E/G ratio of 3.30 and a beta of 0.33. The company has a 50 day moving average of $569.10 and a 200 day moving average of $489.99.Eli Lilly and Company (NYSE:LLY – Get Free Report) last released its quarterly earnings data on Tuesday, August 8th. The company reported $2.11 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.98 by $0.13. The business had revenue of $8.31 billion during the quarter, compared to analysts’ expectations of $7.58 billion. Eli Lilly and Company had a net margin of 22.01% and a return on equity of 65.00%. The company’s revenue for the quarter was up 28.1% on a year-over-year basis. During the same period in the previous year, the company earned $1.25 EPS. As a group, research analysts forecast that Eli Lilly and Company will post 6.65 EPS for the current fiscal year.(Free Report)Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes.Receive News &amp; Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.Eli Lilly and Company Shares Purchased by Oxbow Advisors LLCTruWealth Advisors LLC Has $323,000 Stake in Lowe’s Companies, Inc.1,180 Shares in Texas Instruments Incorporated Purchased by W Advisors LLCDeere &amp; Company Shares Acquired by EverSource Wealth Advisors LLCPark Place Capital Corp Has $797,000 Stake in The Procter &amp; Gamble CompanyU.S. Capital Wealth Advisors LLC Grows Position in iShares 20+ Year Treasury Bond ETFComplete the form below to receive the latest headlines and analysts' recommendations for Eli Lilly and Company with MarektBeat's free daily email newsletter:

Skip to main contentPosted by onOxbow Advisors LLC grew its holdings in Eli Lilly and Company (NYSE:LLY – Free Report) by 6.6% in the second quarter, according to its most recent disclosure with the Securities &amp; Exchange Commission. The fund owned 845 shares of the company’s stock after buying an additional 52 shares during the period. Oxbow Advisors LLC’s holdings in Eli Lilly and Company were worth $396,000 as of its most recent filing with the Securities &amp; Exchange Commission.Several other hedge funds and other institutional investors have also recently modified their holdings of...

Eli Lilly and Company (NYSE:LLY) Shares Purchased by Oxbow Advisors LLC

No article scores yet.

CRITIC REVIEWS

PUBLIC REVIEWS